Journal of Molecular and Clincial Medicine

an Open Access journal of IMR Press
Print ISSN: 2616-3632 | Electronic ISSN: 2617-5282

Special Issue

# Cancer Precision Medicine

Deadline: 31 December 2022

Guest Editor

**Diego Fernández Lázaro, MD**

Department of Cellular Biology, Histology and Pharmacology, Faculty of Health Sciences, University of Valladolid, Campus of Soria, 42003 Soria, Spain
Neurobiology Research Group, Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain

diego.fernandez.lazaro@uva.es

Dear Colleagues,

In recent years there has been an increase in the knowledge of cancer, accompanied by a technological development that has given rise to medical oncology. technological development resulting in Precision Medicine (PM). PM is a course of treatment designed specifically for an individual patient or subpopulation based on a particular genotype or specific biomarkers that might be indicative of the course of the disorder. Precision medicine uses novel biomarkers, targeted disease mechanisms, pharmacogenomics and pharmacogenetics for early diagnosis, appropriate treatment selection, monitoring of response to therapy, progression and prognosis. Its role in disease diagnosis, management, monitoring and prognosis has become more important in recent years due to the rise of omics fields, such as proteomics, metabolomics, genomics and transcriptomics, which have allowed PM to establish reliability. as a developing domain. The use of new biomarkers in cancer disease has allowed individualized therapies and prognostics to become more prevalent, increasing the accuracy of diagnostics and the efficacy of PM-based interventions.

Dr. Diego Fernández Lázaro

*Guest Editor*